title: Comparison of bone morphogenetic protein-2 and osteoactivin for mesenchymal cell differentiation: effects of bolus and continuous administration.
abstract: Current osteoinductive protein therapy utilizes bolus administration of large doses of bone morphogenetic proteins (BMPs), which is costly, and may not replicate normal bone healing. The limited in vivo biologic activity of BMPs requires the investigation of growth factors that may enhance this activity. In this study, we utilized the C3H10T1/2 murine mesenchymal stem cell line to test the hypotheses that osteoactivin (OA) has comparable osteoinductive effects to bone morphogenetic protein-2 (BMP-2), and that sustained administration of either growth factor would result in increased osteoblastic differentiation as compared to bolus administration. Sustained release biodegradable hydrogels were designed, and C3H10T1/2 cells were grown on hydrogels loaded with BMP-2 or OA. Controls were grown on unloaded hydrogels, and positive controls were exposed to bolus growth factor administration. Cells were harvested at several time points to assess osteoblastic differentiation. Alkaline phosphatase (ALP) staining and activity, and gene expression of ALP and osteocalcin were assessed. Treatment with OA or BMP-2 resulted in comparable effects on osteoblastic marker expression. However, cells grown on hydrogels demonstrated osteoblastic differentiation that was not as robust as cells treated with bolus administration. This study shows that OA has comparable effects to BMP-2 on osteoblastic differentiation using both bolus administration and continuous release, and that bolus administration of OA has a more profound effect than administration using hydrogels for sustained release. This study will lead to a better understanding of appropriate delivery methods of osteogenic growth factors like OA for repair of fractures and segmental bone defects.
authors.affiliation: Department of Otolaryngology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA. oneida.arosarena@temple.edu
authors.forename: Oneida A
authors.initials: OA
authors.lastname: Arosarena
authors.forename: Fabiola E
authors.initials: FE
authors.lastname: Del Carpio-Cano
authors.forename: Raul A
authors.initials: RA
authors.lastname: Dela Cadena
authors.forename: Mario C
authors.initials: MC
authors.lastname: Rico
authors.forename: Emeka
authors.initials: E
authors.lastname: Nwodim
authors.forename: Fayez F
authors.initials: FF
authors.lastname: Safadi
mesh_terms: D000469:Alkaline Phosphatase / Q000096:biosynthesis / Q000235:genetics; D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage*; D002454:Cell Differentiation / Q000187:drug effects* / Q000235:genetics; D002460:Cell Line; D003692:Delayed-Action Preparations; D005136:Eye Proteins / Q000008:administration & dosage*; D015870:Gene Expression / Q000187:drug effects; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate / Q000008:administration & dosage; D008562:Membrane Glycoproteins / Q000008:administration & dosage*; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000187:drug effects*; D051379:Mice; D015675:Osteocalcin / Q000096:biosynthesis / Q000235:genetics
chemical_list: D055396:Bone Morphogenetic Protein 2; D003692:Delayed-Action Preparations; D005136:Eye Proteins; C445671:Gpnmb protein, mouse; D008562:Membrane Glycoproteins; D015675:Osteocalcin; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D000469:Alkaline Phosphatase